MERTK as a novel therapeutic target in head and neck cancer

Although head and neck cancer (HNSCC) is the sixth most common tumor entity worldwide therapy options remain limited leading to 5-year survival rates of only 50 %. MERTK is a promising therapeutic target in several tumor entities, however, its role in HNSCC has not been described yet. The aim of our...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Autores principales: von Mässenhausen, Anne, Sanders, Christine, Thewes, Britta, Deng, Mario, Queisser, Angela, Vogel, Wenzel, Kristiansen, Glen, Duensing, Stefan, Schröck, Andreas, Bootz, Friedrich, Brossart, Peter, Kirfel, Jutta, Heasley, Lynn, Brägelmann, Johannes, Perner, Sven
Formato: Artigo
Lenguaje:Inglês
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5078043/
https://ncbi.nlm.nih.gov/pubmed/27081701
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8724
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares